Epizyme (EPZM) scheduled a $60 million IPO with a market capitalization of $375 million (excludes 6.4 million stock option shares) at a price range mid-point of $14, for Friday, May 31, 2013.
S-1 filed May 21, 2013
Manager, Joint Managers: Citi; Cowen; Leerink Swann
Co Managers: JMP; Wedbush PacGrow
SUMMARY
EPZM appears to on the road to developing a drug for certain types of cancers, including hematological cancers and solid tumors. It looks like EPZM's objective is to treat not only the symptoms but also the underlying causes of certain types of cancer.
HISTORY
Strong collaborators
EPZM was founded in November 2007. EPZM has entered into therapeutic collaborations with Celgene Corporation and Celgene International Sàrl, Eisai Co., Ltd., and Glaxo Group Limited [an affiliate of GlaxoSmithKline (GSK)], that has provided EPZM with $120 million in non-equity funding through March 31, 2013.
Market Data 
Markets 
AI
